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論 文 内 容 の 要 旨 
〔 目 的 〕 
 Small bowel transplantation (SBTx) has become the treatment of choice for patients experiencing 
life-threatening complications of intestinal failure.  As another type of immune response in SBTx, 
graft-versus-host disease (GVHD) often occurs after SBTx.  GVHD is mediated by donor derived T cells 
recognizing host MHC alloantigens, and represents an important immunological event influencing life in 
experimental and clinical situation.  We evaluated the possibility that a new sphingosine 1-phosphate receptor 
agonist, FTY720, could diminish GVHD in a rat SBTx model through traffic alteration of donor-derived T cells in 
target organs. 
〔 方法 〕 
 Heterotopic SBTx was performed using a parent (WF)-into-F1 (WF×ACI) rat combination.  The protocol 
comprised 4 groups : Group A, syngeneic group (n＝6) ; Group B, untreated GVHD control group (n＝8) ; Group C, 
F1 recipient rats treated with FTY720 by a low dose of 0.1 mg/kg (n＝6) ; Group D, F1 recipient rats treated with 
FTY720 by a high dose of 0.5 mg/kg (n＝10).  FTY720 administered to the recipient for 14 days after operation.  
Recipient survival, body weight and histopathology were measured.  Flow cytometry was used for the analysis 
of donor-derived T-cell subpopulation from target organs and graft.  Cytokine production from the cultured 
supernatants of target tissue lymphocytes were also compared with untreated controls by ELISA. 
〔結 果〕 
 Untreated control recipients died of GVHD within a mean survival time of 16±1.69 days.  FTY720-treated 
recipients displayed a significantly higher survival rate up to 34.1 days (P＜0.05) when a lower dose of FTY720 
(0.1 mg/kg) was administered for 2 weeks.  Furthermore, recipients also had an obviously higher survival rate of 
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>100 days at a higher dose of FTY720 (0.5 mg/kg ; P＜0.01).  FTY 720 (0.5 mg/kg)-treated group demonstrated 
significant inhibition of histopathological changes in the small bowel, liver and skin, resulting in an almost 
intact architecture.  In the target organs of host, increased numbers and percentages of donor-derived TCRαβ
＋ T cells, CD4＋ T cells and CD8＋ T cells in the liver, MLN and LP, in addition to CD4＋ T cells in PP, during 
GVHD were significantly reduced by FTY720 treatment.  In the graft, however, percentages of donor-derived 
TCRαβ＋ T cells and CD4＋ T cells were increased to 62% and 48% in the MLN, and to 38% and 37% in the LPL 
by FTY720 treatment, respectively.  After administration of FTY720, production of IFN-γ in all the sites of 
target organs was significantly diminished as compared with untreated rats.  However, no significant 
differences in IL-4 production were observed between FTY720-treated and untreated recipients 
〔 総 括 〕 
１. FTY720 inhibited lethality and histopathological changes in target organs when administered at 0.5 mg/kg, 
possibly due to sequestration of donor-derived T cells in the intestinal graft. 
２. FTY720 caused a significant reduction in donor T-cell numbers in target organs by promoting these cells to 
home into donor, but not recipient, secondary lymphoid tissues. 
３. FTY720 significantly decreased production of IFN-γ in target organs. 
We concluded that FTY720 effectively reduced recirculation of activated donor-derived T cells and redistributed 
into target organs of GVHD in SBTx.  These properties may offer the potential to treat ongoing GVHD in small 
bowel transplantation. 
論 文 審 査 の 結 果 の 要 旨 
 本研究では、Wistar Furth（WF）から F1（WFxACI）への近交系ラット異所性小腸移植 GVHD モデル用いて、




を抑制したと考えられた。本研究成果は、小腸移植の急性 GVHD における FTY720 によるドナーT 細胞抑制機序の
重要な知見を示したものであり、学位の授与に値するものと認める。 
